Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by comedian Wayne Brady. Contestants can choose from one of three doors, one of which usually has a nice prize behind it -- but at least one door also typically hides a total dud.
Choosing between Johnson & Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) isn't easy, but it's not nearly as bad as the game show. None of these three big drug stocks are duds. And investors can see what each has to offer without relying on blind luck. Which is the better buy? Here's how J&J, Pfizer, and Gilead compare in three key areas.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
148,90 €
0,11 %
Klare Kaufstimmung für Johnson & Johnson: Viel mehr Buy- als Sell-Einschätzungen.
Das Community-Kursziel von 194 € für Johnson & Johnson deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 148.9 € hin.
